Discovery of novel GSK-3β inhibitors with potent in vitro and in Vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening

Journal of Medicinal Chemistry

Volumn 53, Issue 24, 2010, Pages 8534-8545

  Khanfar, Mohammad A ^a   Hill, Ronald A ^a   Kaddoumi, Amal ^a   El Sayed, Khalid A ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ANILINO 5 PHENYL 1,3,4 OXADIAZOLE; CYCLIN DEPENDENT KINASE 2; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; OXADIAZOLE DERIVATIVE; PHENYLMETHYLENE HYDANTOIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; GLYCOGEN LIVER LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ANILINE COMPOUNDS; ANIMALS; BLOOD-BRAIN BARRIER; DATABASES, FACTUAL; GLYCOGEN SYNTHASE KINASE 3; HYDANTOINS; LIGANDS; LIVER GLYCOGEN; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; OXADIAZOLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STEREOISOMERISM;

EID: 78650342503     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100941j     Document Type: Article

References (55)

1. Ishiguro, K.; Shiratsuchi, A.; Sato, S.; Omori, A.; Arioka, M.; Kobayashi, S.; Uchida, T.; Imahori, K. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments FEBS Lett. 1993, 325, 167-172
2. Lovestone, S.; Reynolds, C. H.; Latimer, D.; Davis, D. R.; Anderton, B. H.; Gallo, J.-M.; Hanger, D.; Mulot, S.; Marquardt, B. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells Curr. Biol. 1994, 4, 1077-1086
3. Klein, P. S.; Melton, D. A. A molecular mechanism for the effect of lithium on development Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8455-8459
4. Pap, M.; Cooper, G. M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway J. Biol. Chem. 1998, 273, 19929-19932
5. Welsh, G. I.; Proud, C. G. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B Biochem. J. 1993, 294, 625-629
6. Wagman, A. S.; Johnson, K. W.; Bussiere, D. E. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes Curr. Pharm. Des. 2004, 10, 1105-1137
7. Li, X.; Lu, F.; Tian, Q.; Yang, Y.; Wang, Q.; Wang, J. Z. Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture J. Neural Transm. 2006, 113, 93-102
8. Neary, J. T. Kang, Yuan. P2 purinergic receptors signal to glycogen synthase kinase-3beta in astrocytes J. Neurosci. Res. 2006, 84, 515-524
9. Martinez, A.; Castro, A.; Dorronsoro, I.; Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation Med. Res. Rev. 2002, 22, 373-384
10. Martinez, A.; Alonso, M.; Castro, A.; Perez, C.; Moreno, F. J. First non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease J. Med. Chem. 2002, 45, 1292-1299
11. Naerum, L.; Norskov-Lauritsen, L.; Olesen, P. H. Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors Bioorg. Med. Chem. Lett. 2002, 12, 1525-1528
12. Witherington, J., 3-Amino Pyrazoles as Potent and Selective Glycogen Kinase Synthase 3 (GSK-3) Inhibitors. In Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors; Martinez, A.; Castro, A.; Medina, M., Eds.; John Wiley & Sons, Inc.: New York, 2006; pp 281-305.
13. Khanfar, M. A.; Abuasal, B.; Mudit, M; Kaddoumi, A; El Sayed, K. Marine natural-derived inhibitors of glycogen synthase kinase-3β phenylmethylene hydantoins: In vitro and in vivo activities, pharmacophore modeling, and virtual screening studies Bioorg. Med. Chem. 2009, 17, 6032-6039
14. Martinez, A.; Alonso, M.; Castro, A.; Dorronsoro, I.; Gelpi, J. L.; Luque, F. J.; Perez, C.; Moreno, F. J. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors J. Med. Chem. 2005, 48, 7103-7112
15. Olesen, P. H.; Sorensen, A. R.; Urso, B.; Kurtzhals, P.; Bowler, A. N.; Ehrbar, U.; Hansen, B. F. Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1 H -[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors J. Med. Chem. 2003, 46, 3333-3341
16. Berg, S.; Hellberg, S. Preparation of N -(4-methoxybenzyl)- N ′-(5-nitro-1,3-thiazol-2-yl)urea for treating conditions associated with glycogen-synthase kinase-3 (GSK3). PCT Int. Appl. WO 2003004478, 2003.
17. O'Neill, D. J.; Shen, L.; Prouty, C.; Conway, B. R.; Westover, L.; Xu, J. Z.; Zhang, H. C.; Maryanoff, B. E.; Murray, W. V.; Demarest, K. T.; Kuo, G. H. Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl- maleimides as potent and selective glycogen synthase kinase-3β (GSK-3β) inhibitors Bioorg. Med. Chem. 2004, 12, 3167-3185 (Pubitemid 38680706)
18. Nuss, J. M.; Harrison, S. D.; Ring, D. B.; Boyce, R. S.; Brown, S. P.; Goff, D.; Johnson, K.; Pfister, K. B.; Ramurthy, S.; Renhowe, P. A.; Seely, L.; Subramanian, S.; Wagman, A. S.; Zhou, X. A. Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors. PCT Int. Appl. WO 9965897, 1999.
19. Gentles, R. G.; Hu, S.; Dubowchik, G. M. Recent advances in the discovery of GSK-3 inhibitors and a perspective on their utility for the treatment of Alzheimer's disease Annu. Rep. Med. Chem. 2009, 44, 3-26
20. Godemann, R.; Biernat, J.; Mandelkow, E.; Mandelkow, E. M. Phosphorylation of tau protein by recombinant GSK-3beta: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain FEBS Lett. 1999, 454, 157-164
21. Gong, C. X.; Lidsky, T.; Wegiel, J.; Zuck, L.; Grundke-Iqbal, I.; Iqbal, K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease J. Biol. Chem. 2000, 275, 5535-5544
22. Iqbal, K.; Grundke-Iqbal, I. Inhibition of neurofibrillary degeneration: A promising approach to Alzheimer's disease and other tauopathies Curr. Drug Targets 2004, 5, 495-502
23. Phiel, C. J.; Wilson, C. A.; Lee, V.M-Y.; Klein, P. S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides Nature 2003, 423, 435-439
24. Takashima, A.; Noguchi, K.; Michel, G.; Mercken, M.; Hoshi, M.; Ishiguro, K.; Imahori, K. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta Neurosci. Lett. 1996, 203, 33-36
25. Culbert, A, A.; Brown, M. J.; Frame, S.; Hagen, T.; Cross, D. A. E.; Bax, B.; Reith, A. D. GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces tau dephosphorylation and beta-catenin stabilization without elevation of glycogen synthase activity FEBS Lett. 2001, 507, 288-294
26. Alvarez, G.; Munoz-Montano, J. R.; Satrustegui, J.; Avila, J.; Bogonez, E.; Diaz-Nido, J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration FEBS Lett. 1999, 453, 260-264
27. Medina, M.; Castro, A. Glycogen synthase kinase-3 (GSK-3) 1045 inhibitors reach the clinic Curr. Opin. Drug Discovery Dev. 2008, 11, 533-543
28. Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors J. Mol. Biol. 2003, 333, 393-407
29. Taha, M. O.; Bustanji, Y.; Al-Ghussein, M. A. S.; Mohammad, M.; Zalloum, H.; Al-Masri, I. M.; Atallah, N. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin J. Med. Chem. 2008, 51, 2062-2077
30. Kim, H.-J.; Choo, H.; Cho, Y. S.; No, K. T. i.; Pae, A. N. Novel GSK-3beta inhibitors from sequential virtual screening Bioorg. Med. Chem. 2008, 16, 636-643
31. Patel, D. S.; Bharatam, P. V. New leads for selective GSK-3 inhibition: pharmacophore mapping and virtual screening studies J. Comput.-Aided Mol. Des. 2006, 20, 55-66
32. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26 (Pubitemid 33653411)
33. Chekler, E. L. P.; Elokdah, H. M.; Butera, J. Efficient one-pot synthesis of substituted 2-amino-1,3,4-oxadiazoles Tetrahedron Lett. 2008, 49, 6709-6711
34. van der Waterbeemd, H. Quantitative approaches to structure-activity relationships. In The Practice of Medicinal Chemistry; Wermuth, C. G., Ed.; Academic Press: London, 1996; p 367.
35. Martin, Y. C.; Bures, M. G.; Danaher, E. A.; DeLazzer, J.; Lico, I.; Pavlik, P. A. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists J. Comput.-Aided Mol. Des. 1993, 7, 83-102
36. Clark, R. D. OptiSim: an extended dissimilarity selection method for finding diverse representative subsets J. Chem. Inf. Comput. Sci. 1997, 37, 1181-1188
37. Marriott, D. P.; Dougall, I. G.; Meghani, P.; Liu, Y.-J.; Flower, D. R. Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists J. Med. Chem. 1999, 42, 3210-3216
38. Spadoni, G.; Balsamini, C.; Diamantini, G.; Di Giacomo, B.; Tarzia, G.; Mor, M.; Plazzi, P. V.; Rivara, S.; Lucini, V.; Nonno, R.; Pannacci, M.; Fraschini, F.; Stankov, B. M. Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study J. Med. Chem. 1997, 40, 1990-2002
39. Gadakar, P. K.; Phukan, S.; Dattatreya, P.; Balaji, V. N. Pose prediction accuracy in docking studies and enrichment of actives in the active site of GSK-3beta J. Chem. Inf. Model. 2007, 47, 1446-5149
40. Polgar, T.; Baki, A.; Szendrei, G. I.; Keseru, G. M. Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors J. Med. Chem. 2005, 48, 7946-7959
41. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormoe, M.; Nilsson, Y.; Radesaeter, A.; Jerning, E.; Markgren, P. O.; Borgegard, T.; Nyloef, M.; Gimenez-Cassina, A.; Hernandez, F.; Lucas, J. J.; Diaz-Nido, J.; Avila, J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 J. Biol. Chem. 2003, 278, 45937-45945
42. Meijer, L.; Skaltsounis, A. L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X. P.; Vonica, C. A.; Brivanlou, A.; Dajani, R.; Crovace, C.; Tarricone, C.; Musacchio, A.; Roe, S. M.; Pearl, L.; Greengard, P. GSK-3-Selective inhibitors derived from tyrian purple indirubins Chem. Biol. 2003, 10, 1255-1266
43. Jain, A. N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine J. Med. Chem. 2003, 46, 499-511
44. Tripos Associates. SYBYL Molecular Modeling Software, version 8.0; Tripos Associates: St. Louis, MO, 2007; http://www.tripos.com.
45. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation J. Mol. Biol. 1995, 245, 43-53
46. Shultz-Gasch, T.; Stahl, M. Binding site characteristics in structure-based virtual screening: evaluation of current docking tools J. Mol. Model. 2003, 9, 47-57
47. Rodems, S. M.; Hamman, B. D.; Lin, C.; Zhao, J.; Shah, S.; Heidary, D.; Makings, L.; Stack, J. H.; Pollok, B. A. A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases Assay Drug Dev. Technol. 2002, 1, 9-19
48. Hamann, M. T.; Alonso, D.; Martín-Aparicio, E.; Fuertes, A.; Pérez-Puerto, J.; Castro, A.; Morales, S.; Navarro, M. L.; del Monte-Millán, M.; Medina, M.; Pennaka, H.; Balaiah, A.; Peng, J.; Cook, J.; Wahyuono, S.; Martínez, A. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease J. Nat. Prod. 2007, 70, 1397-1405
49. Lawrie, A. M.; Noble, M. E.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 Nature Struct. Biol. 1997, 4, 796-801
50. Ravitz, M. J.; Wenner, C. E. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta Adv. Cancer Res. 1997, 71, 165-207
51. Lochhead, P. A.; Coghlan, M.; Rice, S. Q. J.; Sutherland, C. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenol-ypyruvate carboxykinase gene expression Diabetes 2001, 50, 937-946
52. Saitoh, M.; Kunitomo, J.; Kimura, E.; Hayase, Y.; Kobayashi, H.; Uchiyama, N.; Kawamoto, T.; Tanaka, T.; Mol, C. D.; Dougan, D. R.; Textor, G. P.; Snell, G. P.; Itoh, F. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β Bioorg. Med. Chem. 2009, 17, 2017-2029
53. Saitoh, M.; Kunitomo, J.; Kimura, E.; Iwashita, H.; Uno, Y.; Onishi, T.; Uchiyama, N.; Kawamoto, T.; Tanak, T.; Mol, C. D.; Dougan, D. R.; Textor, G. P.; Snell, G. P.; Takizawa, M.; Itoh, F.; Kori, M. 2-{3-[4-(Alkylsulfinyl)phenyl]- 1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β with good brain permeability J. Med. Chem. 2009, 52, 6270-6286
54. Mylonas, S.; Mamalis, A. Synthesis and antitumor activity of new thiosemicarbazones of 2-acetylimidazo[4,5- b ]pyridine J. Heterocycl. Chem. 2005, 42, 1273-1281
55. Carroll, N. V.; Longley, R. W.; Roe, J. H. The determination of glycogen in liver and muscle by use of anthrone reagent J. Biol. Chem. 1956, 220, 583-593